Vivitrol's Opioid Abuse Claim Will Likely Need Monitoring and Support Services
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Psychopharmacologic Drugs Advisory Committee voted in favor of expanding the indication for Alkermes' alcoholism treatment by lopsided margins, with the caveat that monitoring and support must be provided to patients.